Mankind Pharma has released its investor presentation for Q2 and H1 FY27, showcasing robust financial performance. Key highlights include a 17.3% YoY revenue growth for Q2 FY27, reaching INR 4,338 crore. The company also reported significant increases in EBITDA and PAT, along with strong performance in its domestic and international businesses. Strategic updates on expansion and new product launches were also detailed.
Mankind Pharma Reports Strong Q2 & H1 FY27 Performance
Mankind Pharma has unveiled its investor presentation for the second quarter and first half of the financial year 2027 (Q2 & H1 FY27), detailing significant financial achievements and strategic business updates. The company reported a total revenue of INR 4,338 crore for Q2 FY27, marking a notable 17.3% year-on-year growth. This performance underscores the company’s steady expansion and market penetration.
Key Financial Highlights
The financial snapshot for Q2 FY27 reveals substantial improvements across key metrics. Revenue from operations stood at INR 4,338 crore, with a year-on-year growth of 17.3%. EBITDA saw a considerable increase of 27.2% to INR 1,175 crore, while Profit After Tax (PAT) grew by an impressive 37.7% to INR 716 crore. EBITDA margins improved by 210 bps to 27.1%, indicating enhanced operational efficiency.
Segmental Performance and Business Updates
The presentation detailed strong performance across business segments. Domestic business (excluding Consumer Healthcare) grew by 15.9%, driven by double-digit growth in both Mankind and BSV specialty businesses. Key focused brands showed robust growth, with acute brands like Pantakind (31%) and chronic brands like Pangraf (60%) leading the charge. BSV’s key brands also demonstrated healthy growth. International business revenue surged by 33% in Q2 FY27, supported by strong growth in both Mankind and BSV international operations. The company also announced the launch of one new product in Q2 FY27, bringing its total launched products in the US to 50.
Strategic Expansion and Future Outlook
Mankind Pharma emphasized its consistent expansion into specialty and super specialty segments. The company highlighted its high entry barrier portfolio with a specialty R&D tech platform and its #1 or #2 ranking in 9 key brand families within the BSV segment. Consumer Healthcare segment revenue was INR 229 crore in Q2 FY27, with market share gains in key brands like Manforce and Preganews. The company is strategically focusing on enhancing its chronic share and expanding its product portfolio, including a significant entry into Next-Generation CAR-T therapies through the acquisition of Armed Cell Therapeutics.
Source: BSE
